Longitudinal Renal Function in Liver Transplant Recipients With Acute-on-Chronic Liver Failure

  • Masahiko Yazawa
    James D. Eason Transplant Institute, Methodist University Hospital, Memphis, Tennessee, USA;
  • Benedict Maliakkal
    James D. Eason Transplant Institute, Methodist University Hospital, Memphis, Tennessee, USA;
  • Satheesh Nair
    James D. Eason Transplant Institute, Methodist University Hospital, Memphis, Tennessee, USA;
  • Pradeep S. B. Podila
    Faith & Health Division, Methodist Le Bonheur Healthcare, Memphis, Tennessee, USA;
  • Uchenna A. Agbim
    James D. Eason Transplant Institute, Methodist University Hospital, Memphis, Tennessee, USA;
  • Saradasri Karri
    Department of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA;
  • Sabrina D. Khan
    Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, USA;
  • Daniel Maluf
    James D. Eason Transplant Institute, Methodist University Hospital, Memphis, Tennessee, USA;
  • James D. Eason
    James D. Eason Transplant Institute, Methodist University Hospital, Memphis, Tennessee, USA;
  • Miklos Z. Molnar
    James D. Eason Transplant Institute, Methodist University Hospital, Memphis, Tennessee, USA;
  • Sanjaya K. Satapathy
    Sandra Atlas Bass Center for Liver Diseases & Transplantation, Department of Medicine, Northshore University Hospital/Northwell Health, Manhasset, New York, USA.

Description

<jats:sec> <jats:title>INTRODUCTION:</jats:title> <jats:p>To analyze the impact of acute-on-chronic liver failure (ACLF) immediately before liver transplantation (LT) on short-term kidney function.</jats:p> </jats:sec> <jats:sec> <jats:title>METHODS:</jats:title> <jats:p>In this retrospective study, we included 416 of 687 consecutive patients who had an estimated glomerular filtration rates (eGFRs) at 3-month post-LT. We compared the non-ACLF (N = 356), ACLF with eGFR ≥30 mL/min/1.73 m<jats:sup>2</jats:sup> (A-HGFR, N = 32), and ACLF with eGFR <30 mL/min/1.73 m<jats:sup>2</jats:sup> (A-LGFR, N = 28) groups at LT and for 2 kidney-related outcomes: (i) slope of eGFR by linear mixed model and (ii) time to development of composite kidney outcomes (eGFR < 15 mL/min/1.73 m<jats:sup>2</jats:sup> or need for dialysis).</jats:p> </jats:sec> <jats:sec> <jats:title>RESULTS:</jats:title> <jats:p>The mean eGFRs at LT in non-ACLF, A-HGFR, and A-LGFR groups were significantly different as follows: 83.9 ± 29.5, 56.5 ± 31.2, and 21.6 ± 5.0 mL/min/1.73 m<jats:sup>2</jats:sup>, respectively. The eGFR slope significantly increased in A-LGFR group (+7.26 mL/min/1.73 m<jats:sup>2</jats:sup>/mo), whereas it remained stable in A-HGFR group (+1.05 mL/min/1.73 m<jats:sup>2</jats:sup>/mo) and significantly declined in non-ACLF group (−7.61 mL/min/1.73 m<jats:sup>2</jats:sup>/mo) by the first 3-month period. On the other hand, the eGFR slope in all groups stabilized after 3 months post-LT. A-LGFR group showed significantly increased risk of developing composite kidney outcomes in adjusted analysis (hazard ratio = 3.61, 95% confidence interval: 1.35–9.70) compared with the non-ACLF group. However, this significance disappeared after the further adjustment for eGFR at 3-month post-LT (hazard ratio = 1.91, 95% confidence interval: 0.70–5.23).</jats:p> </jats:sec> <jats:sec> <jats:title>DISCUSSION:</jats:title> <jats:p>The slopes of eGFR before 3-month post-LT were significantly different among non-ACLF, A-HGFR, and A-LGFR groups. The renal dysfunction in A-LGFR group stabilized after partial recovery by 3-month post-LT (eGFR reset point).</jats:p> </jats:sec>

Journal

Citations (1)*help

See more

Details 詳細情報について

Report a problem

Back to top